TPST News and Press, Tempest Therapeutics Inc.

BRISANE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest” or “Tempest Therapeutics”) today announced the appointment of two independent directors, Drake Richey and John Yee, MD, MPH to its Board of Directors (the “Bo...

BRISBANE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (the “Company”), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, today announced the entry a definitive agreem...

2026-05-14 16:37:05 ET More on Tempest Therapeutics Tempest Therapeutics announces up to $6M private placement Seeking Alpha’s Quant Rating on Tempest Therapeutics Historical earnings data for Tempest Therapeutics Financial information for Tempest Ther...

Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myeloma (rrMM) Announced Cincinnati Children’s Applied Gene and Cell Therapy Center (“AGCTC”) as Lead Manufacturing Partner Appointed ...

2026-05-11 18:50:06 ET Tempest Therapeutics, Inc. (TPST) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 4.29%. The average open to low on the day of earnings was -3.19%. The average ope...

100% complete response (“CR”) rate among all 15 CAR-T-naïve efficacy evaluable patients treated with TPST-2003 dual-targeting CD19/BCMA CAR-T across two ongoing Phase 1 trials (REDEEM-1 and POEMS-1) Favorable safety profile with no Grade > 3 CRS or ICANS in REDEEM-1 ...

Presentation will showcase recent data from multiple clinical studies evaluating dual-targeting CD19/BCMA CAR-T therapy candidate TPST-2003 Results support clinical benefit of parallel-structure dual-targeting CAR architecture in patients with relapsed/refractory multiple myeloma Data furth...

Delivery of TPST-2003 lentiviral vector to Cincinnati Children’s Applied Gene and Cell Therapy Center enables manufacturing activities required for pivotal development Tech transfer on track to support initiation of potentially registrational study in Q4 2026 Key manufacturing milest...

Adds dedicated business development leadership to support Tempest’s strategic priorities Will lead China outreach and cross-border partnership efforts To support ongoing partnering discussions for Phase 3-ready amezalpat program, including potential China development opportunities ...

2026-03-30 09:09:47 ET More on Tempest Therapeutics Tempest Therapeutics announces up to $6M private placement Seeking Alpha’s Quant Rating on Tempest Therapeutics Historical earnings data for Tempest Therapeutics Financial information for Tempest Ther...